Compare · Head-to-head
Follistatin vs Ipamorelin.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Ipamorelin, then use the table to confirm fit.
Ipamorelin is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01· Subject
Follistatin
Myostatin/activin antagonist — human work is largely via gene therapy, not consumer peptide vials.
01 · At a glance
| Decision factor | Follistatin | Ipamorelin |
|---|---|---|
| Primary fit | muscle growth & strength research where you want a clear starting point | muscle growth & strength and fat loss & metabolism comparisons |
| Evidence | Tier C-D | Tier B-C |
| Risk | extreme | high |
| Experience level | advanced | intermediate |
| Budget tier | premium | mid |
| Administration route | subcutaneous | subcutaneous, intravenous |
02 · Use case & timing
| Decision factor | Follistatin | Ipamorelin |
|---|---|---|
| Goal fit | Muscle Growth & Strength | Muscle Growth & Strength, Fat Loss & Metabolism, GH Axis Optimization |
| What users compare it for | Myostatin inhibition / muscle growth narrative. Legitimate modality is gene therapy, not RUO peptide. | GH-axis biomarker modulation. Body composition effects are speculative in consumer context. |
| Onset timeline | Gene therapy effects measured over months. Consumer peptide timelines are speculative. | GH pulse effects are acute; body composition claims are long-horizon and not well-established. |
| Main tradeoff | Potential upside comes with much more safety and screening caution than lower-risk alternatives. | Potential upside comes with much more safety and screening caution than lower-risk alternatives. |
03 · Safety & restrictions
| Decision factor | Follistatin | Ipamorelin |
|---|---|---|
| Adverse effects | Systemic muscle-growth modulation carries theoretical off-target risks; extreme risk. | Immunogenicity risk (FDA); impurity concerns with unnatural amino acids; glucose/cortisol axis concerns. |
| Contraindications | No consumer-grade data. | No established label contraindications (not approved). |
| Interaction notes | Unknown; likely interacts with anabolic pathways and endocrine status. | High uncertainty; glucose/cortisol axis monitoring concerns consistent with secretagogue class. |
| Regulatory status | Not approved | Not approved |
| FDA flag | FDA status unclear | FDA compounding caution |
| WADA status | Status unclear | WADA S2 |
04 · Age & monitoring
| Decision factor | Follistatin | Ipamorelin |
|---|---|---|
| Supported age ranges | No age guidance yet | 25-34, 35-44, 45-54 |
| Life-stage note | Not yet documented | Usually framed as a lower-friction GH secretagogue, but age still increases the burden of monitoring and risk review. |
| Monitoring burden | Not specified | high |
| Follow-up cadence | Not yet documented | Frequent early review, then periodic reassessment every few months. |
05 · Cost & sourcing
| Decision factor | Follistatin | Ipamorelin |
|---|---|---|
| Typical cycle cost | No reliable estimate yet | $180.00 |
| Estimated monthly cost | No reliable estimate yet | $60.00 |
| Cost confidence | No estimate | High confidence |
06 · Before you buy
| Decision factor | Follistatin | Ipamorelin |
|---|---|---|
| Tracked vendor listings | 0 listings | 3 listings |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.